Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical Trial

Secondary analysis of the phase 3 DART trial: postoperative ctHPVDNA MRD positivity was associated with worse 24-month PFS (69.5% vs 95.9%), and 3-month post-treatment detection was strongly associated with PFS (HR 20.48).

JAMA Otolaryngol Head Neck SurgPubMed 40402484DOI 10.1001/jamaoto.2025.0903